MET and lung carcinoma: METex14-altered lung cancer has been identified in patients expressing PD-L1 (n = 147; PD-L1 expression, 0%, 1–49%, and 50% accounting for 37%, 22%, and 41%, respectively, across 111 evaluable tumor samples); however, neither interaction nor complex formation was detected between c-MET and PD-L1 [11].